♦ Switching to B/F/TAF is safe, effective and well tolerated in virologically suppressed adults ≥ 65 years through 48 weeks (N=140)
-High virologic suppression at 92% with no virologic failures and no treatment-emergent resistance
-No renal, bone, or hepatic AEs resulting in discontinuation
-Only one drug-related AEs occurred that led to discontinuation
-No drug-related AEs that were serious or Grade 3 or 4
-Median weight change of 1 kg plateaued at Week 36 and was consistent with observed trends over time in the general population
-Modest improvement in fasting lipid parameters
♦ These data support the use of B/F/TAF for treatment of adults ≥65 years who could benefit from a small single-tablet with few drug-drug interactions and an established safety profile
